论文部分内容阅读
[目的]探讨Fas/FasL系统在非小细胞肺癌(NSCLC)发生发展中所起的免疫逃逸作用,为临床早期诊断肺癌、判断预后、设计新的治疗策略提供依据。[方法]采用免疫组织化学方法检测Fas、FasL在NSCLC组织及正常肺组织中的表达,同时采用抗CD45RO抗体检测肿瘤组织中浸润淋巴细胞(tumor infiltrating lymphocytes,TIL)的数量。[结果]与正常肺组织比,Fas在肺癌组织低表达(51.25%vs.100.00%)并存在异位表达,表达率与细胞分化有关。FasL在肺癌组织中高表达(67.50%vs.0),表达率和细胞类型及淋巴结转移相关,与TIL浸润程度呈负相关。[结论]NSCLC组织中普遍存在Fas表达的下调、异位表达及FasL高表达,导致癌细胞逃脱机体免疫系统的监视,参与NSCLC的发生和发展。
[Objective] To investigate the role of Fas / FasL in immune escape in the development of non-small cell lung cancer (NSCLC) and to provide basis for early clinical diagnosis of lung cancer, prognosis and design of new therapeutic strategies. [Method] The expressions of Fas and FasL in NSCLC tissues and normal lung tissues were detected by immunohistochemistry. Meanwhile, the number of TILs in tumor tissues was detected by anti-CD45RO antibody. [Results] Compared with normal lung tissue, Fas expression in lung cancer was low (51.25% vs.100.00%) and there was ectopic expression, the expression rate was related to cell differentiation. FasL was highly expressed in lung cancer (67.50% vs.0). The expression of FasL was correlated with cell type and lymph node metastasis, and negatively correlated with the degree of TIL infiltration. [Conclusion] Down-regulation of Fas expression, ectopic expression and high expression of FasL in NSCLC tissues lead to cancer cells escaping the surveillance of the immune system and participating in the occurrence and development of NSCLC.